AWM
ABBV icon

Aberdeen Wealth Management’s AbbVie ABBV Stock Holding History

Aberdeen Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.53M Sell
11,628
-50
-0.4% -$11.1K 1.15% 17
2025
Q4 		$2.67M Sell
11,678
-325
-3% -$74K 1.24% 16
2025
Q3 		$2.78M Hold
12,003
– – 1.75% 14
2025
Q2 		$2.23M Sell
12,003
-336
-3% -$62.4K 1.48% 15
2025
Q1 		$2.59M Sell
12,339
-97
-0.8% -$18.9K 1.78% 11
2024
Q4 		$2.21M Sell
12,436
-559
-4% -$103K 1.51% 14
2024
Q3 		$2.57M Sell
12,995
-1,997
-13% -$373K 1.69% 10
2024
Q2 		$2.57M Buy
14,992
+53
+0.4% +$8.78K 1.74% 11
2024
Q1 		$2.72M Buy
14,939
+1,503
+11% +$259K 1.58% 12
2023
Q4 		$2.08M Sell
13,436
-1,547
-10% -$226K 1.51% 12
2023
Q3 		$2.23M Buy
14,983
+3
+0% +$440 1.68% 12
2023
Q2 		$2.02M Buy
14,980
+3
+0% +$440 1.46% 14
2023
Q1 		$2.39M Sell
14,977
-97
-0.6% -$14.8K 1.78% 10
2022
Q4 		$2.44M Sell
15,074
-1,957
-11% -$300K 1.84% 10
2022
Q3 		$2.29M Buy
17,031
+3
+0% +$430 2.01% 9
2022
Q2 		$2.61M Buy
17,028
+3
+0% +$458 2.07% 9
2022
Q1 		$2.76M Buy
17,025
+3
+0% +$436 1.88% 10
2021
Q4 		$2.31M Buy
17,022
+3
+0% +$354 1.5% 14
2021
Q3 		$1.84M Sell
17,019
-292
-2% -$33.4K 1.78% 11
2021
Q2 		$1.95M Buy
17,311
+3
+0% +$338 1.8% 13
2021
Q1 		$1.87M Sell
17,308
-420
-2% -$44.9K 1.49% 15
2020
Q4 		$1.9M Buy
17,728
+420
+2% +$40.4K 1.43% 14
2020
Q3 		$1.52M Buy
17,308
+4
+0% +$377 1.44% 18
2020
Q2 		$1.7M Buy
17,304
+56
+0.3% +$4.93K 1.82% 10
2020
Q1 		$1.31M Sell
17,248
-230
-1% -$19.6K 1.6% 13
2019
Q4 		$1.55M Buy
+17,478
New +$1.45M 1.15% 14

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aberdeen Wealth Management's ABBV Position: Q1 2026 in Review

Aberdeen Wealth Management reduced its AbbVie (ABBV) stake by 0.43% in Q1 2026, selling an estimated $11.1K and leaving 11,628 shares worth $2.53M. The position accounts for 1.15% of the portfolio, ranked #17.

Aberdeen Wealth Management first reported a position in ABBV in Q4 2019 and has held it in 26 quarters since. The position peaked at $2.78M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Aberdeen Wealth Management held 11,628 shares of AbbVie worth $2.53M as of Q1 2026.
  • Aberdeen Wealth Management sold 50 AbbVie shares in Q1 2026, an estimated $11.1K.
  • AbbVie made up 1.15% of Aberdeen Wealth Management's portfolio in Q1 2026, its #17 holding.
  • Aberdeen Wealth Management first reported a position in AbbVie in Q4 2019 and has held it in 26 quarters since.
  • Aberdeen Wealth Management's AbbVie position peaked at $2.78M in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Aberdeen Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.